Luis Chia, Senior Director of Global Commercial Development, Early Pipeline and Exploratory Indications at Revolution Medicines, shared on LinkedIn:
“I’m excited to share that I’ve joined Revolution Medicines as Senior Director, Global Commercial Development, Early Pipeline and Exploratory Indications.
A few weeks in, I’m already energized by the science and the opportunity ahead. Like many of us in pharma, I first learned about the challenge of targeting RAS back in graduate school. For decades, RAS was considered ‘undruggable,’ despite being one of the most common drivers of cancer.
Seeing how advances in the science are turning that long-standing challenge into a real therapeutic opportunity was a big part of what drew me to RevMed.
I’m excited to be part of a team pushing the boundaries of targeted oncology, working at the forefront of RAS biology while exploring where the science and technology can take us next. There’s a lot to build, and I’m looking forward to bringing together scientific, clinical, and commercial perspectives to help shape the pipeline and translate scientific advances into better outcomes for patients.
It’s been a great start, and I’m grateful to the team for making me feel so welcome. Excited for what we’ll build together.”
Other articles about Revolution Medicines on OncoDaily.